Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

Budroni, Sonia; Buricchi, Francesca; Cavallone, Andrea; Bourguignon, Patricia; Caubet, Magalie; Dewar, Vincent; D’Oro, Ugo; Finco, Oretta; Garçon, Nathalie; El Idrissi, Mohamed; Janssens, Michel; Leroux-Roels, Geert; Marchant, Arnaud; Schwarz, Tino; Van Damme, Pierre; Volpini, Gianfranco; van der Most, Robbert; Didierlaurent, Arnaud M.; Burny, Wivine

Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4(+) T cell response durability, and recall responses to non-adjuvanted fractional-dose antigen administered 1-year post-immunization (Day [D]360), between hepatitis B vaccines containing Adjuvant System (AS)01(B), AS01(E), AS03, AS04, or Alum (NCT00805389). Both the antibody and B cell levels ranked similarly (AS01(B/E)/AS03 > AS04 > Alum) at peak response, at D360, and following their increases post-antigen recall (D390). Proportions of high-avidity antibodies increased post-dose 2 across all groups and persisted at D360, but avidity maturation appeared to be more strongly promoted by AS vs. Alum. Post-antigen recall, frequencies of subjects with high-avidity antibodies increased only markedly in the AS groups. Among the AS, total antibody responses were lowest for AS04. However, proportions of high-avidity antibodies were similar between groups, suggesting that MPL in AS04 contributes to avidity maturation. Specific combinations of immunoenhancers in the AS, regardless of their individual nature, increase antibody persistence and avidity maturation.